Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis-Reference-Cited by-同舟云学术

Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis

Published:2018-03-13 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Min Se Hee,Yoon Jeong-Hwa,Moon Sun Joon,Hahn Seokyung,Cho Young Min^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-22658-2.pdf

Reference28 articles.

1. Defronzo, R. A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773–795, https://doi.org/10.2337/db09-9028 (2009).

2. Abdul-Ghani, M. A., Norton, L. & Defronzo, R. A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr. Rev. 32, 515–531, https://doi.org/10.1210/er.2010-0029 (2011).

3. Tahrani, A. A., Barnett, A. H. & Bailey, C. J. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1, 140–151, https://doi.org/10.1016/S2213-8587(13)70050-0 (2013).

4. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705, https://doi.org/10.1016/s0140-6736(06)69705-5 (2006).

5. Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13, 7–18, https://doi.org/10.1111/j.1463-1326.2010.01306.x (2011).

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review;International Journal of Diabetes and Technology;2024-04

2. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial;International Journal of Diabetes in Developing Countries;2024-02-17

3. Acacia leucophloea (Roxb.). Willd.: Multi-targeted therapeutic efficacy against type 2 diabetes mellitus;European Journal of Integrative Medicine;2024-02

4. Expert consensus recommendations on the evaluation and management of hypoglycemia in diabetes: DGENius Group Diabetes India;Journal of Diabetology;2024-01

5. The Current Place of DPP4 Inhibitors in the Evolving Landscape of Type 2 Diabetes Management: Is It Time to Bid Adieu?;American Journal of Cardiovascular Drugs;2023-09-08